Six senators are railing on Sanofi for its role in a Zika pricing dustup that’s gained considerable attention since last year.
Takeda has been eyeing India’s vaccine market since at least 2015, and the idea has come to fruition in the form of two licensing deals.
Clinical care experts and patient advocacy organizations call attention to why better patient understanding shapes the best integrated approach to orphan drug…
BiondVax secured a €20 million loan from the European Investment Bank to advance its universal flu vaccine candidate.
Bristol-Myers Squibb's Opdivo is in more vaccine combo studies than its PD-1/PD-L1 rivals, according to a new report.
Brought to you by the publisher of FierceBiotech and FiercePharma, the Fierce Innovation Awards Life Sciences Edition identify and showcase outstanding…
A Sanofi executive has explained the rationale behind the company’s Zika vaccine development plan and is issuing a defense against claims his company is out to…
European biotech Vaximm has partnered with much bigger drug companies Merck KGaA and Pfizer to test a cancer vaccine/checkpoint inhibitor combo.
Serum Institute of India CEO Adar Poonawalla struck a deal on Tuesday to pick up a defunct Czech outfit for €72 million.
Bavarian Nordic has licensed a cell line from Valneva to help it manufacture vaccines based on its modified vaccinia Ankara vaccine platform.
GlaxoSmithKline’s U.S. vaccine R&D head Ripley Ballou says emerging disease vaccine research needs a shakeup—and here's how.
The U.S. government is pumping more money into anthrax bioterror preparedness.